Colony-Stimulating Factors for the Treatment of Stroke

Colony-stimulating factors in the pathogenesis and treatment of disease.

Treatment of Crohn’s disease with colony-stimulating factors: An overview

Current treatments for Crohn's disease are aimed at suppressing excessive immune activation in the bowel walls. However, alternative strategies can be drawn. These involve the augmentation of the innate immune response, in the hypothesis that patients affected with Crohn's disease are characterized by a relative immunodeficiency, with failure of the defensive barrier to luminal microbes and mic...

Haemopoietic colony stimulating factors for preterm neonates.

Bacterial and fungal sepsis is a major cause of morbidity and mortality in neonates. Infection rates are high in infants treated in intensive care units, with the highest rates, of around 30%, occurring in extremely immature preterm neonates. A survey of neonatal infection at Yale University, ongoing since 1928, has documented a decline in neonatal septic deaths commensurate with the establishm...

Developing granulocyte-colony stimulating factor for the treatment of stroke: current status of clinical trials.

Developing Granulocyte-Colony Stimulating Factor for the Treatment of Stroke: Current Status of Clinical Trials To the Editor: The review of Solaroglu et al1 on granulocyte-colony stimulating factor (G-CSF) as novel neuroprotectant is important, and the fact that it comes from a group not involved in primary research in this field illustrates the growing attention of the general stroke communit...

STUDIES ON THE TISSUE SPECIFICITY OF COLONY STIMULATING FACTOR

In this study granulocyte-macrophage colony stimulating factor (CSF) was prepared from rabbit and guinea pig lung tissues. The biological activity of these CSFs was measured on semisolid agar culture and compared with those of mouse and rat. Weight of animals, incubation time and cross-reactivity of CSFs with different bone marrow sources were also investigated. The results showed that both...